Are Weight Loss Medications Safe? Understanding the Evidence

Safety is one of the most common concerns when considering weight loss medication. Treatments such as Wegovy (semaglutide) and Mounjaro (tirzepatide) have been widely studied, but it is important to understand both their benefits and their potential risks.

Weight loss medications are not new, but newer treatments work in a more targeted way by influencing appetite and metabolic pathways. For a general overview of how these medications work, see our guide How Weight Loss Medications Work: A Medical Overview.

How safety is assessed
Before any medication is approved for use in the UK, it must go through extensive clinical trials to assess both effectiveness and safety. Regulatory bodies review this evidence before allowing medications to be prescribed.

For weight loss medications, large scale clinical trials have evaluated both semaglutide and tirzepatide in a range of patients. These studies provide important data on weight loss outcomes, side effects, and longer term safety.

What the current evidence shows
Clinical trials have shown that GLP-1 based medications can lead to meaningful weight loss for many people. They have also been shown to improve markers such as blood sugar levels and, in some cases, cardiovascular risk factors.

However, like all medications, they are not without risk. Understanding these risks is an important part of making an informed decision.

Common side effects
The most commonly reported side effects are related to the digestive system. These include nausea, vomiting, diarrhoea, constipation, and reduced appetite.

These symptoms are usually mild to moderate and often improve over time, particularly when the medication dose is increased gradually. We explore this in more detail in our guide to managing side effects of weight loss medication.

Less common but important risks
Less common side effects may include gallbladder issues, dehydration, or more significant gastrointestinal symptoms. These are not experienced by most people, but they are important to be aware of.

This is why ongoing medical supervision is essential when using weight loss medication.

Who should not take weight loss medication
Weight loss medications are not suitable for everyone. Certain medical conditions, medications, or personal health factors may mean that treatment is not appropriate.

A full medical assessment is required before starting treatment to ensure it is safe and suitable.

Wegovy vs Mounjaro safety
Both Wegovy and Mounjaro have been studied extensively, but they act on slightly different pathways. Mounjaro targets both GLP-1 and GIP receptors, while Wegovy works on GLP-1 alone.

Safety profiles are broadly similar, although individual experiences can vary. For more detail on how these medications differ, see our article Mounjaro Explained: How It Differs From Other Weight Loss Medications.

Emerging medications and long term safety
New treatments such as retatrutide are currently being studied. While early results are promising, long term safety data is still being collected, and these medications are not yet approved for routine use in the UK.

Balancing benefits and risks
When considering any treatment, it is important to weigh the potential benefits against the risks. For many people, the health risks associated with untreated obesity may be greater than the risks associated with medication.

This is why weight loss medication is considered as part of a broader medical approach, rather than a standalone solution.

Medication as part of a wider plan
Weight loss medications work best alongside nutrition, physical activity, sleep, and stress management. They should be used as part of a structured and supported plan.

For a full overview of how medication fits into long term treatment, see our pillar guide Weight Loss Medication in the UK: A Patient-Centred Pillar Guide.

Further reading
• NICE guidance on obesity management
• NHS weight management services
• Clinical trials for semaglutide and tirzepatide